medigraphic.com
Federación Mexicana de Ginecología y Obstetricia, A.C.

2005, Number 08

<< Back Next >>

Ginecol Obstet Mex 2005; 73 (08)

Selective estrogen receptors modulators (SERMs): biochemistry, pharmacology, and clinical use in gynecology

Terán DJ, Teppa GAD

Language: Spanish
References: 63
Page: 424-435
PDF size: 98.68 Kb.


ABSTRACT

The selective strogen receptors modulators (SERMs) were initially developed as antistrogens for the treatment of breast cancer, but their unusual properties have led to their use in the treatment and prevention of other diseases as well. SERMs bind the strogen receptor (ER) and modulated ER-mediated gene transcription. Tamoxifen is an effective treatment for hormone responsive breast cancer and can prevent breast cancer in high-risk women. Raloxifene was approved for the prevention and treatment of osteoporosis in postmenopausal women, also appears to prevent breast cancer. Other SERMs are in development, with the goal of improving efficacy and reducing toxicity.


REFERENCES

  1. Top S, Vessieres A, Pigeon P, Rager MN, Huche M, Salomon E, et al. Selective estrogen-receptor modulators (SERMs) in the cyclopentadienylrhenium tricarbonyl series: synthesis and biological behaviour. Chembiochem 2004;5:1104-13.

  2. Speroff L, Glass RH, Kase NG. Clinical ginecologic endocrinology and infertility. 6th ed. Philadelphia: Lippincott Williams & Wilkins, 1999.

  3. Buckley MM, Goa KL. Tamoxifen: A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use. Drugs 1989;37:451-90.

  4. Hall JM, McDonnell DP. The estrogen receptor beta-isoform (ER beta) of the human estrogen receptor modulates ER alfa transcriptional activity and is a regulator of the cellular response to estrogen and antiestrogens. Endocrinology 1999;140:5566-78.

  5. King MC, Wieand S, Hale K, Lee M, Walsh T, Owens K, et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA-1 and BRCA-2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1). Breast Cancer Prevention Trial. JAMA 2001;286:2251-6.

  6. Shang Y, Brown M. Molecular determinants for the tissue specificity of SERMs. Science 2002;295:2465-8.

  7. Montano M, Muller V, Trobaugh A. The carboxy-terminal F domain of the human estrogen receptor: Role in the transcripcional activity of the receptor and the effectiveness of antiestrogens as estrogen antagonists. Mol Endocrinol 1995;9:814-25.

  8. Osborne CK, Zhao HH, Fuqua SAW. Selective estrogen receptor modulators: structure, function, and clinical use. J Clin Oncol 2000;18:3172-86.

  9. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-88.

  10. Koshizuka K, Serizawa M, Hasuda N, Furuya K, Mouri N, Takano K, et al. Tamoxifen-induced severe hypertriglyceridemia-report of 3 cases. Gan To Kagaku Ryoho 2004;31:1109-12.

  11. Saphner T, Tormey DC, Gray R. Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol 1991;9:286-91.

  12. Veronesi U, Maisonneuve P, Sacchini V, Rotmensz N, Boyle P and the Italian Tamoxifen Study Group. Tamoxifen for breast cancer among hysterectomised women. Lancet 2002;359:1122-4.

  13. Veronesi U, Maisonneuve P, Rotmensz N, Costa A, Sacchini V, Travaglini R, et al. Italian randomized trial among women with hysterectomy: tamoxifen and hormone-dependent breast cancer in high-risk women. J Natl Cancer Inst 2003;95:160-5.

  14. Powles TJ, Eeles R, Ashley S, Easton D, Chang J, Dowsett M, et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 1998;352:98-101.

  15. International Breast Cancer Intervention Study (IBIS-I). First results from the IBIS-I: a randomised prevention trial. Lancet 2002;360:817-24.

  16. Cuzick J, Powles TJ, Veronesi U, Forbes J, Edwards R, Ashley S, et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet 2003;361:296-300.

  17. Boostanfar R, Jain JK, Mishell DR, Paulson RJ. A prospective randomized trial comparing clomiphene citrate with tamoxifen citrate for ovulation induction. Fertil Steril 2001;75:1024-26.

  18. Marttunen MB, Hietanen P, Tiitinen A, Ylikorkala O. Comparison of effects of tamoxifen and toremifene on bone biochemistry and bone mineral density in postmenopausal breast cancer patients. J Clin Endocrinol Metab 1998;83:1158-62.

  19. Dhandapani K, Brann D. Neuroprotective effects of estrogen and tamoxifen in vitro: a facilitative role for glia? Endocrine 2003;21:59-66.

  20. Wong C, Lai T, Hilly JM, Stewart CE, Farndon JR. Selective estrogen receptor modulators inhibit the effects of insulin-like growth factors in hyperparathyroidism. Surgery 2002;132:998-1006.

  21. Gysler M, March CM, Mishell DR, Bailey EJ. A decade’s experience with an individualized clomiphene treatment regiment including its effects on the postcoital test. Fertil Steril 1982;37:161-7.

  22. Vogel CL, Shemano L, Schoenfelder J. Multicenter phase II efficacy trial of toremifene in tamoxifen-refractary patients. J Clin Oncol 1993;11:345-50.

  23. Rauschning W, Pritchard KI. Droloxifeno, a new antiestrogen: Its role in metastatic breast cancer. Breast cancer Res Treat 1994;31:83-94.

  24. Chander SK, McCague R, Luqmani Y. Pyrrolidino-4-iodotamoxifen and 4-iodotamoxifen, new analogues of the antiestrogen tamoxifen for the treatment of breast cancer. Cancer Res 1999;51:5851-8.

  25. Toko T, Sugimoto Y, Matsuo K, Yamasaki R, Takeda S, Wierzba K, et al. TAT-59, a new triphenylethylene derivate with antitumor activity against hormone-dependent tumors. Eur J Cancer 1990;26(397-404.).

  26. Wilson TM, Henke BR, Momtahen TM. 3-(4-(1,2-diphenylbut-1-enyl)phenyl)acrylic acid: A non-esteroidal estrogen with functional selectivity for bone over uterus in rats. J Med Chem 1994;37:1550-2.

  27. Ammann P, Bourrin S, Bonjour JP, Brunner F, Meyer JM, Rizzoli R. The new selective estrogen receptor modulator MDL 103,323 increases bone mineral density and bone strength in adult ovariectomized rats. Osteoporos Int 1999;10:369-76.

  28. Bitonti AJ, Baumann RJ, Bush TL, Cashman EA, Wright CL, Prakash NJ. Antitumor and chemopreventive effects of a clomiphene analog, MDL 103,323, in mammary carcinoma. Anticancer Res 1996;16:2553-7.

  29. Black LJ, Jones CD, Folcone JF. Antagonism of estrogen action with a new benzothiophene-derived antiestrogen. Life Sci 1983;32:1031-6.

  30. Dhingra K. Antiestrogens: Tamoxifen, SERMs and beyond. Invest New Drugs 1999;17:285-311.

  31. Yang NN, Venugopalan M, Hardikar S, Glasebrook AL. Identification of an estrogen response element activated by metabolites of 17-beta-estradiol and raloxifene. Science 1996;273:1222-5.

  32. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. Results from a 3-year randomized clinical trial. JAMA 1999;282:637-45.

  33. 33 Barrett-Connor E, Grady D, Sashegyi A, Anderson PW, Cox DA, Hoszowski K, et al. Raloxifene and cardiovascular events in osteoporotic postmenopausal women. Four-year results from the MORE randomized trial. JAMA 2002;287:847-57.

  34. Cummings SR, Eckert SE, Krueger KA, Grady D, Powles TJ, Cauley JA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women. Results from the MORE randomized trial. JAMA 1999;281:2189-97.

  35. Riggs BL, Hartmann LC. Selective estrogen-receptor modulators. Mechanisms of action and application to clinical practice. N Engl J Med 2003;348:518-29.

  36. Walsh BW, Paul S, Wild RA, Dean RA, Tracy RP, Cox DA, et al. The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab 2000;85:214-8.

  37. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002;347:1557-65.

  38. Mosca L, Barrett-Connor E, Wenger NK, Collins P, Grady D, Komitzer M, et al. Design and methods of the Raloxifene Use for the Heart (RUTH) study. Am J Cardiol 2001;88:392-5.

  39. Neele SJ, Evertz R, Genazzani AR, Luisi M, Netelenbos C. Raloxifene treatment increases plasma levels of beta-endorphin in postmenopausal women: a randomized, placebo-controlled study. Fertil Steril 2002;77:1110-7.

  40. Weisinger JR, Heilberg IP, Hernández E, Carlini R, Bellorin-Font E. Selective estrogen receptor modulators in chronic renal failure. Kidney Int Suppl 2003;Jun:62-65.

  41. Labrie F, Labrie C, Belanger A, Simard J, Gauthier S, Luu-The V, et al. EM-652 (SCH 57068), a third generation SERM acting as pure antiestrogen in the mammary gland and endometrium. J Steroid Biochem Molec Biol 1999;69:51-84.

  42. Tatchum-Talom R, Martel C, Labrie F, Marette A. Acute vascular effects of the selective estrogen receptor modulator EM-652 (SCH 57068) in the rat mesenteric vascular bed. Cardiovasc Res 2003;57:535-43.

  43. Palkowitz AD, Glasebrook AL, Thrasher KJ, Hauser KL, Short LL, Phillips DL, et al. Discovery and synthesis of [6-hydroxy-3-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-2-(4-hydroxyphenyl)]b enzo[b]thiophene: a novel, highly potent, selective estrogen receptor modulator. J Med Chem 1997;40:1407-16.

  44. Ke HZ, Paralkar VM, Grasser WA, Crawford DT, Qi H, Simmons HA, et al. Effects of CP-336,156, a new, nonsteroidal estrogen agonist/antagonist, on bone, serum cholesterol, uterus, and body composition in rats models. Endocrinology 1998;139:2068-76.

  45. Morello KC, Wurz GT, DeGregorio MW. Pharmacokinetics of selective estrogen receptor modulators. Clin Pharmacokinet 2003;42:361-72.

  46. Komi J, Heikkinen J, Rutanen EM, Halonen K, Lammintausta R, Ylikorkala O. Effects of ospemifene, a novel SERM, on biochemical markers of bone turnover in healthy postmenopausal women. Gynecol Endocrinol 2004;18:152-8.

  47. Wakelin AE. Use of pure antioestrogens to elucidate the mode of action of oestrogens. Biochem Pharmacol 1995;49:1545-9.

  48. Wakelin AE. The future of new pure antioestrogens in clinical breast Cancer. Breast Cancer Res Treat 1993;25:1-9.

  49. Wuttke W, Jarry H, Becker T, Schultens A, Christoffel V, Gorkow C, et al. Phytoestrogens: endocrine disrupters or replacement for hormone replacement therapy? Maturitas 2003;44:S9-S20.

  50. Renaud J, Bischoff SF, Buhl T, Floersheim P, Fournier B, Halleux C, et al. Estrogen receptor modulators: Identification and structure-activity relationships of potent ER alpha-selective tetrahydroisoquinoline ligands. J Med Chem 2003;46:2945-57.

  51. Blizzard TA, Morgan JD, Mosley RT, Birzin ET, Frisch K, Rohrer SP, et al. 2-Phenylspiroindenes: a novel class of selective estrogen receptor modulators (SERMs). Bioorg Med Chem Lett 2003;13:479-83.

  52. Ozolins TR, Gupta U. Embryo/fetal toxicity assessment of lasofoxifene, a selective estrogen receptor modulator (SERM), in rats and rabbits. Birth Defects Res Part B Dev Reprod Toxicol 2004;71:161-70.

  53. Zhang JX, Labaree DC, Mor G, Hochberg RB. Estrogen to antiestrogen with a single methylene group resulting in an unusual steroidal selective estrogen receptor modulator. J Clin Endocrinol Metab 2004;89:3527-35.

  54. Fisher B, Dignam J, Wolmark N, Wickerham DL, Fisher ER, Mamounas E, et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Projet B-24 randomised controlled trial. Lancet 1999;353:1993-2000.

  55. Ravdin PM, Green S, Dorr TM, McGuire WL, Fabian C, Pugh RP, et al. Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: Results of a prospective Southwest Oncology Group Study. J Clin Oncol 1992;10:1284-91.

  56. Vogel CL. Phase II and III clinical trials of toremifene for metastatic breast cancer. Oncology 1998;12:9-13.

  57. Gradishar WJ, Glusman FE, Vogel CL. Raloxifene HCL, a new endocrine agent, is active in estrogen receptor positive (ER +) metastatic breast cancer. Breast Cancer Res Treat 1997;46:53 (abstr 209).

  58. Münster PN, Buzdar A, Dhingra K, Enas N, Ni L, Major M, et al. Phase I study of a third-generation selective estrogen receptor modulator, LY353381.HCL, in metastatic breast cancer. J Clin Oncol 2001;19:2002-9.

  59. Howell A, Robertson J. Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer. Lancet 1995;345:989-90.

  60. Early Breast Cancer Trialists Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998;351:1451-67.

  61. Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med 1998;339:1609-18.

  62. Rivera JA, Christopoulos S, Small D, Trifiro M. Hormonal manipulation of benign metastasizing leiomyomas: report of two cases and review of the literature. J Clin Endocrinol Metab 2004;89:3183-8.

  63. Meegan MJ, Lloyd DG. Advances in the science of estrogen receptor modulation. Curr Med Chem 2003;10:181-210.




2020     |     www.medigraphic.com